These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

369 related items for PubMed ID: 24958518

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence.
    Togashi Y, Hayashi H, Nakagawa K, Nishio K.
    Drug Des Devel Ther; 2014; 8():1037-46. PubMed ID: 25114510
    [Abstract] [Full Text] [Related]

  • 4. Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs).
    Martínez-Navarro EM, Rebollo J, González-Manzano R, Sureda M, Evgenyeva E, Valenzuela B, Fernández FJ, Forteza J, Brugarolas A.
    Clin Transl Oncol; 2011 Nov; 13(11):812-8. PubMed ID: 22082647
    [Abstract] [Full Text] [Related]

  • 5. Optimal management of patients with non-small cell lung cancer and epidermal growth factor receptor mutations.
    Lin CC, Yang JC.
    Drugs; 2011 Jan 01; 71(1):79-88. PubMed ID: 21175241
    [Abstract] [Full Text] [Related]

  • 6. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
    Chen G, Kronenberger P, Teugels E, Umelo IA, De Grève J.
    BMC Med; 2012 Mar 21; 10():28. PubMed ID: 22436374
    [Abstract] [Full Text] [Related]

  • 7. Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations.
    Liang W, Wu X, Fang W, Zhao Y, Yang Y, Hu Z, Xue C, Zhang J, Zhang J, Ma Y, Zhou T, Yan Y, Hou X, Qin T, Dinglin X, Tian Y, Huang P, Huang Y, Zhao H, Zhang L.
    PLoS One; 2014 Mar 21; 9(2):e85245. PubMed ID: 24533047
    [Abstract] [Full Text] [Related]

  • 8. Management and future directions in non-small cell lung cancer with known activating mutations.
    Gerber DE, Gandhi L, Costa DB.
    Am Soc Clin Oncol Educ Book; 2014 Mar 21; ():e353-65. PubMed ID: 24857124
    [Abstract] [Full Text] [Related]

  • 9. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M, Okamoto I, Tsurutani J, Oiso N, Kawada A, Nakagawa K.
    Jpn J Clin Oncol; 2012 Jun 21; 42(6):528-33. PubMed ID: 22457323
    [Abstract] [Full Text] [Related]

  • 10. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
    Chang LC, Lim CK, Chang LY, Chen KY, Shih JY, Yu CJ.
    Eur J Cancer; 2019 Sep 21; 119():77-86. PubMed ID: 31425965
    [Abstract] [Full Text] [Related]

  • 11. Experience with afatinib in patients with non-small cell lung cancer progressing after clinical benefit from gefitinib and erlotinib.
    Schuler M, Fischer JR, Grohé C, Gütz S, Thomas M, Kimmich M, Schneider CP, Laack E, Märten A, Afatinib Compassionate Use Consortium.
    Oncologist; 2014 Oct 21; 19(10):1100-9. PubMed ID: 25232040
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Afatinib: A first-line treatment for selected patients with metastatic non-small-cell lung cancer.
    Engle JA, Kolesar JM.
    Am J Health Syst Pharm; 2014 Nov 15; 71(22):1933-8. PubMed ID: 25349236
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.
    Yasuda H, Park E, Yun CH, Sng NJ, Lucena-Araujo AR, Yeo WL, Huberman MS, Cohen DW, Nakayama S, Ishioka K, Yamaguchi N, Hanna M, Oxnard GR, Lathan CS, Moran T, Sequist LV, Chaft JE, Riely GJ, Arcila ME, Soo RA, Meyerson M, Eck MJ, Kobayashi SS, Costa DB.
    Sci Transl Med; 2013 Dec 18; 5(216):216ra177. PubMed ID: 24353160
    [Abstract] [Full Text] [Related]

  • 20. Lifestyle risks exposure and response predictor of gefitinib in patients with non-small cell lung cancer.
    Ying H, Yang XD, Sun Z, Ning X, Wang Y, Bai C, Chen S, Wang Y.
    Med Oncol; 2014 Oct 18; 31(10):220. PubMed ID: 25216867
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.